Focus Partners Wealth
RVPH

Focus Partners Wealth’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History

Focus Partners Wealth’s Portfolio RVPH Stock Details RVPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,650
Closed -$14.8K – 2818
2025
Q4 		$14.8K Hold
2,650
– – ﹤0.01% 2635
2025
Q3 		$19.5K Hold
2,650
– – ﹤0.01% 2188
2025
Q2 		$20.2K Sell
2,650
-350
-12% -$5.45K ﹤0.01% 2006
2025
Q1 		$57.2K Hold
3,000
– – ﹤0.01% 1836
2024
Q4 		$109K Sell
3,000
-5,050
-63% -$141K ﹤0.01% 1790
2024
Q3 		$232K Hold
8,050
– – ﹤0.01% 1402
2024
Q2 		$206K Sell
8,050
-500
-6% -$22.7K ﹤0.01% 1156
2024
Q1 		$646K Buy
8,550
+2,500
+41% +$198K 0.01% 673
2023
Q4 		$623K Buy
+6,050
New +$543K 0.01% 540

Other funds holding RVPH

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WAM
Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Focus Partners Wealth's RVPH Position: Q1 2026 in Review

Focus Partners Wealth sold out of REVIVA PHARMA HLDGS INC (RVPH) in Q1 2026, closing a stake of 2,650 shares — an estimated $14.8K sold.

Focus Partners Wealth first reported a position in RVPH in Q4 2023 and held it in 9 quarters. The position peaked at $646K in Q1 2024. 35 funds tracked by Wall St. Rank hold RVPH as of Q1 2026.

  • Focus Partners Wealth reported no remaining REVIVA PHARMA HLDGS INC position as of Q1 2026 after selling out during the quarter.
  • Focus Partners Wealth sold 2,650 REVIVA PHARMA HLDGS INC shares in Q1 2026, an estimated $14.8K.
  • Focus Partners Wealth first reported a position in REVIVA PHARMA HLDGS INC in Q4 2023 and held it in 9 quarters.
  • Focus Partners Wealth's REVIVA PHARMA HLDGS INC position peaked at $646K in Q1 2024.
  • 35 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q1 2026.

Based on Focus Partners Wealth's 13F filing for Q1 2026, filed 15 May 2026.